Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction-Beijing Jiuzhitang Maker Cell

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction

With a license granted by CardioCell LLC (a shareholding company of Stemedica) to treat cardiovascular indications with it-hMSCs, ALTACO XXI from Kazakhstan successfully completed a Phase III clinical trial in Kazakhstan and submitted an application for listing the product as a new drug to Kazak authorities. On September 12, 2018, the Ministry of Kazakhstan approved the application of Stemedica manufactured stem cells as a therapy to acute myocardial infarction, officially bringing it-hMSCs into clinical settings.

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction

Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District

Jiuzhitang Maker signed cooperation agreements with Novastem from Mexico and ALTACO from Kazakhstan

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.

Links: Jiuzhitang丨 Mudanjiang Youbo Pharmaceutical 丨 Beijing Tiantan Hospital丨 No.1 Hospital-Harbin Medical Sciences University丨 Stemedica丨

Business License

Online Message